The estimated Net Worth of Ercem Atillasoy is at least $789 Tausend dollars as of 19 October 2022. Dr Atillasoy owns over 2,095 units of AlloVir stock worth over $99,843 and over the last 4 years he sold ALVR stock worth over $116,680. In addition, he makes $572,464 as Chief Regulatory & Safety Officer at AlloVir.
Sign up
Dr D ALVR stock SEC Form 4 insiders trading
Dr has made over 6 trades of the AlloVir stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,095 units of ALVR stock worth $18,268 on 19 October 2022.
The largest trade he's ever made was selling 4,639 units of AlloVir stock on 25 January 2022 worth over $38,225. On average, Dr trades about 1,238 units every 36 days since 2020. As of 19 October 2022 he still owns at least 131,372 units of AlloVir stock.
You can see the complete history of Dr Atillasoy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Ercem Atillasoy M.D. biography
Dr. Ercem Atillasoy M.D. is the Chief Regulatory & Safety Officer at AlloVir.
What is the salary of Dr D?
As the Chief Regulatory & Safety Officer of AlloVir, the total compensation of Dr D at AlloVir is $572,464. There are 3 executives at AlloVir getting paid more, with David L. Hallal having the highest compensation of $981,018.
How old is Dr D?
Dr D is 57, he's been the Chief Regulatory & Safety Officer of AlloVir since . There are 1 older and 6 younger executives at AlloVir. The oldest executive at AlloVir, Inc. is Vikas Sinha C.A., CPA, M.B.A., 58, who is the Pres, CFO & Director.
What's Dr D's mailing address?
Ercem's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Insiders trading at AlloVir
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... und Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
What does AlloVir do?
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
What does AlloVir's logo look like?
Complete history of Dr Atillasoy stock trades at AlloVir
AlloVir executives and stock owners
AlloVir executives and other stock owners filed with the SEC include:
-
David L. Hallal,
Exec. Chairman -
Vikas Sinha C.A., CPA, M.B.A.,
Pres, CFO & Director -
Vikas Sinha,
Pres, CFO & Director -
Dr. Ercem Atillasoy M.D.,
Chief Regulatory & Safety Officer -
Dr. Diana M. Brainard M.D.,
CEO & Director -
Sonia Choi,
Sr. VP of Corp. Affairs & Investor Relations -
Ugo Capolino Perlingieri,
Head & GM of Europe and Middle East Operations -
Dr. Jeroen Van Beek Ph.D.,
Chief Commercial Officer -
Edward Miller,
Gen. Counsel & Sec. -
Medha Chadha M.B.A.,
Sr. VP of Strategic Planning & Investor Relations -
Dr. Ann M. Leen Ph.D.,
Chief Scientific Officer -
Brett R. Hagen,
Chief Accounting Officer -
Agustin Melian M.D.,
Advisor -
Sciences, Inc. Gilead,
10% owner -
Edward Miller,
General Counsel -
Diana Brainard,
Chief Executive Officer -
Llc Elevate Bio,,
Director -
Juan Vera,
-
Group, Llc Green Jeremy Red...,
-
Ann M. Leen,
Chief Scientific Officer -
John Robert Wilson,
Director -
Ercem Atillasoy,
See Remarks -
Beek Jeroen B Van,
Chief Commercial Officer -
Agustin Melian,
Chief Medical Officer -
Brett R Hagen,
Chief Accounting Officer -
Ansbert Gadicke,
Director -
Morana Jovan Embiricos,
-
Vikas Sinha,
See Remarks -
Cintia Piccina,
Chief Commercial Officer -
Shawn Tomasello,
-
Malcolm Brenner,
-
David Hallal,
-
Jeffrey S Bornstein,